30
Mar
2017

Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?
Third Rock’s Revolution Medicines Tears Apart Antifungals, Atom By Atom
Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down